Logo

American Heart Association

  49
  0


Final ID: Mo096

High-Throughput Functional Determination of TNNI3 Variant Pathogenicity

Abstract Body: Introduction
Mutations in the thin filament protein TNNI3 (cardiac troponin I) can perturb calcium cycling and cause hypertrophic, restrictive, and dilated cardiomyopathies. However, the majority of TNNI3 variants observed in patients have unknown functional significance and uncertain contribution to disease. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are a powerful system for studying the effect of genetic variants on human cardiomyocyte function. TNNI3 has been challenging to study in these cells as they predominantly express TNNI1. In this study, we combined a novel scalable in vitro gene replacement method with simultaneous measurement of contractility and calcium cycling to determine the functional effect of TNNI3 variants.

Hypothesis
Using our gene replacement platform, we expect that TNNI3 variants causing Hypertrophic Cardiomyopathy (HCM) will increase force generation and calcium sensitivity relative to wild-type, whereas TNNI3 variants causing Dilated Cardiomyopathy (DCM) will decrease force generation and calcium sensitivity relative to wild-type.

Methods
We generated double knockout TNNI1-/- TNNI3-/- hiPSCs. Cardiomyocytes differentiated from these hiPSCs were transduced with lentivirus carrying either wild-type or mutant TNNI3 during replating onto polyacrylamide gels with fluorescent beads. After a week of incubation, the cells were stained with a fluorescent calcium probe, and contractility, diastolic tension, and calcium sensitivity were measured by our high-throughput physiologic imaging and analysis platform.

Results
hiPSC-CMs expressing the HCM-associated variant R192H show increased peak force, diastolic tension, and calcium sensitivity relative to wild-type TNNI3, whereas hiPSC-CMs expressing the DCM-associated variant K36Q show decreased peak force and calcium sensitivity relative to wild-type TNNI3.

Conclusion
We validated our TNNI3 in vitro gene replacement and high-throughput physiologic imaging and analysis platform by comparing reference HCM and DCM variants to wild-type TNNI3. Ongoing scaled studies will evaluate the naturally occurring variants in ClinVar to characterize their functional effect on cardiac physiology.
  • Staudt, David  ( Stanford Childrens Health , Palo Alto , California , United States )
  • Tran, Peter  ( STANFORD UNIVERSITY , Stanford , California , United States )
  • Han, Dongju  ( STANFORD UNIVERSITY , Stanford , California , United States )
  • Serrano, Ricardo  ( STANFORD UNIVERSITY , Stanford , California , United States )
  • Mercola, Mark  ( STANFORD UNIVERSITY , Stanford , California , United States )
  • Author Disclosures:
    David Staudt: DO NOT have relevant financial relationships | Peter Tran: DO NOT have relevant financial relationships | Dongju Han: DO NOT have relevant financial relationships | Ricardo Serrano: No Answer | Mark Mercola: DO have relevant financial relationships ; Ownership Interest:Regencor, Inc.:Active (exists now) ; Consultant:Cytokinetics:Active (exists now) ; Individual Stocks/Stock Options:Vala Sciences:Active (exists now)
Meeting Info:

Basic Cardiovascular Sciences

2024

Chicago, Illinois

Session Info:

Poster Session and Reception I

Monday, 07/22/2024 , 04:30PM - 07:00PM

Poster Session and Reception

More abstracts on this topic:
You have to be authorized to contact abstract author. Please, Login
Not Available